BNET Industries
Last Fiscal Year Sales:$35.9B
- Public
- DE
Dow Jones Description
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and improved earning power. We already successfully reorganized the Bayer Group and further streamlined our portfolio to create a new Bayer that is focused on its corporate strengths, its customers and the markets of the future. To help us achieve this goal, we then carried out a strategic realignment in order to concentrate in future on three high-potential, agile subgroups with largely independent operations: HealthCare, CropScience and MaterialScience, supported by three service companies. Our operating companies give us the access we need to the growth markets of the future. As an inventor company, we plan to continue setting trends in research-intensive areas. Innovations are the foundation for our competitiveness and our corporate growth, and thus for our success in the future. We believe our technical and commercial expertise entails a duty to contribute to sustainable development ? a principle we wholeheartedly endorse, mindful of its social, ethical and environmental elements. In awareness of our responsibilities as a corporate citizen, we define economy, ecology and social commitment as objectives of equal rank. We seek to retain society?s confidence through performance, flexibility and open communication as we work in pursuit of our overriding corporate goals: to steadily create corporate value and generate high value-added for the benefit of our stockholders, our employees and the community in every country in which we operate.
Director, Finance
Klaus KuhnNumber of Employees 122,100
Peer Companies
NAICS Code Plastics Material and Resin Manufacturing: 325211
Recent Events
-
Bayers Betaferon approved in China for Treatment of Multiple Sclerosis
-
UPDATE 3-US FDA declines to approve Endo testosterone drug
-
UPDATE 1-Futuragene signs licence deal with Bayer CropScience
-
Bayer and United Nations Environment Programme Launch 19th Annual International Children's...
-
Bayer Consumer Care Launches CitracalR Calcium Plus Heart Health
-
German drug, chemical company Bayer's Q3 net income falls 10 per cent
-
Bayer, US Onyx launch phase III trial of Nexavar in patients with non-responsive thyroid cancer
-
BRIEF-Credit Suisse raises targets on European pharma cos
-
Bayer accused of hiding Yaz contraceptive risk
-
Bayer downgraded to neutral from buy at UBS
-
Abbott Laboratories to acquire Solvay Pharmaceuticals
-
Bayer's contested kidney cancer drug shows benefit
-
Bayer names new CEO
-
Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play...
-
Bayer's next CEO has a year to prepare Today
News & Analysis
Filter by
bayer ag and onyx software - All News and Analysis
Bayer to Onyx: You Don't Even Know the Name of the Drug We Didn't Steal From You
Bayer is arguing that it did not steal an analog of its Nexavar cancer drug from development partner Onyx because Onyx got the name of the analog wrong in its lawsuit. Onyx sued Bayer in May, alleging that after the little-cancer-company-that-could had shown Bayer how to make Nexavar sorafenib, Bayer...
Onyx Suit vs. Bayer Reads Like Romance Gone Wrong: "I Want My Baby Back!"
Onyx's lawsuit against Bayer over their joint venture on cancer drug Nexavar reads like a love affair gone wrong -- complete with allegations of Bayer going behind Onyx's back, cheating on the company as it concealed its intent to steal Onyx's baby. by Jim Edwards
Zacks Analyst Blog Highlights: Onyx Pharmaceuticals, Bayer, Pfizer, Wyeth and Genentech
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), Bayer (NYSE: BAY), Pfizer (NYSE: PFE),...
Bayer and Onyx Announce Nexavar® Tablets as Global Trade Name for Investigational Cancer Treatment
WEST HAVEN, Conn. & EMERYVILLE, Calif. -- Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the selection of NexavarR sorafenib tosylate Tablets as the global trade name for sorafenib, the oral investigational drug under FDA review for the treatment of advanced renal cell carcinoma RCC,...
MedImmune to acquire Cellective Therapeutics, Inc. and Bayer, Onyx receive FDA Priority Review.
M2 PRESSWIRE-14 September 2005-US Financial Network: MedImmune to acquire Cellective Therapeutics, Inc. and Bayer, Onyx receive FDA Priority ReviewC1994-2005 M2 COMMUNICATIONS LTD RDATE:14092005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) MedImmune, Inc. (Nasdaq:...
Bayer and Onyx Announce FDA Acceptance of New Drug Application for Sorafenib for Individuals with Advanced Renal Cell Carcinoma.
WEST HAVEN, Connecticut and EMERYVILLE, California, September 14 /PRNewswire/ -- WEST HAVEN, Connecticut and EMERYVILLE, California, September 14 /PRNewswire/ --
Bayer and Onyx Complete Filing of New Drug Application.
M2 PRESSWIRE-11 July 2005-US Financial Network: Bayer and Onyx Complete Filing of New Drug ApplicationC1994-2005 M2 COMMUNICATIONS LTD RDATE:11072005 City of Industry, CA - July 11, 2005 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Bayer Pharmaceuticals ...
Bayer and Onyx Announce Positive Phase II Data in Patients With Advanced Kidney Cancer.
WEST HAVEN, Connecticut., and RICHMOND, California, October 25 /PRNewswire/ -- WEST HAVEN, Connecticut., and RICHMOND, California, October 25 /PRNewswire/ --
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Klaus Kuhn | Director, Finance |
| Richard Pott | Director, Strategy and Human Resources |
| Wolfgang Plischke | Director, Innovation, Technology and Environment |
| Hartmut Klusik | Head, Product Supply |
| Gary S Balkema | Executive Committee Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Arthur J Higgins | Chairman, HealthCare |
| Werner Wenning | Executive Chairman |
| Klaus Kleinfeld | Board of Directors |
| Paul Achleitner | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Finance | Current |
| University of South Carolina | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Strategy and Human Resources | Current |
| University of Cologne | doctorate in physics | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Innovation, Technology and Environment | Current |
| Bayer HealthCare AG | Manager | Current |
| Bayer HealthCare AG | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Head, Product Supply | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Chairman, HealthCare | Current |
| Enzon Pharmaceuticals, Inc. | CEO | Former |
| Pharmaceutical Research and Manufacturers of America | member | Former |
| Bayer HealthCare, Animal Health Division | Chairman | Former |
| Enzon Pharmaceuticals, Inc. | Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Chairman | Current |
| Henkel AG & Co. KGaA | Supervisory Board | Current |
Klaus Kleinfeld is president and chief executive officer of Alcoa. He joined the company in 2007 as president and chief operating officer and seven months later assumed CEO responsibilities. He has served on Alcoa's board of directors since 2003. Alcoa is a world leader in the production and management of a very sustainable product: aluminum. Nearly 75% of the aluminum ever produced since 1888 is still in use today. The company has been a technology leader since its beginning, providing more than 90% of the aluminum alloys used in aircraft and space flight; helping making automobiles lighter, without compromising safety or performance; manufacturing sheet that created the ultimate recyclable container, the aluminum beverage can; and providing building and construction industry materials that help further the green building movement. In addition, to serving customers in these markets, Alcoa also markets wheels, fastening systems, precision and investment castings, and building systems. The company has 97,000 employees in 34 countries. Before coming to Alcoa, Mr. Kleinfeld had a 20-year career with Siemens, the global electronics and industrial conglomerate, based in the U.S. and Germany, where he served as chief executive officer of Siemens AG starting in 2005. During his tenure, Mr. Kleinfeld presided over a dramatic transformation of the company, reshaping the company's portfolio around three high growth areas, resulting in increase of revenues and market capitalization nearly doubled. Prior to his service on the Managing Board of Siemens AG, Mr. Kleinfeld was President and Chief Executive Officer of Siemens Corporation, its U.S. arm and the company's largest region. In addition to serving on Alcoa's board, he is a member of the board of Bayer AG. On the personal front, Mr. Kleinfeld was born in Bremen, Germany and educated at the University of Goettingen and University of Wuerzburg, both in Germany. He holds a Ph.D in strategic management and master's degree in business administration. In his leisure time, he enjoys skiing, tennis, the arts and is a marathon runner. Mr. Kleinfeld resides in New York with his wife and children.
| Organization | Position | Status |
|---|---|---|
| Alcoa, Inc. | President & Chief Executive Officer | Current |
| Bayer AG | Board of Directors | Current |
| Alcoa, Inc. | Board of Directors | Current |
| Siemens AG | President & CEO | Former |
| Siemens Corporation | Chief Executive Officer | Former |
| Alcoa, Inc. | Chief Operating Officer | Former |
| Siemens Corporation | Chief Operating Officer | Former |
| Siemens AG | Chief Operations Officer, U.S. | Former |
| Siemens AG | Executive Vice President | Former |
| Siemens AG | Audit Committee Principal | Former |
| Citigroup Inc. | Board of Directors | Former |
| Siemens AG | Board of Directors | Former |
| Siemens Corporation | member | Former |
| Organization | Position | Status |
|---|---|---|
| Allianz SE | Executive Director, Finance | Current |
| Bayer AG | Board of Directors | Current |
| Goldman, Sachs & Co. | Vice President, Mergers & Acquisitions | Former |
| Bain & Company | Manager, Strategy Consulting | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Committee Member | Current |
| Bayer HealthCare, Animal Health Division | President, Worldwide Bayer Consumer Care Division | Former |
| Fairleigh Dickinson University | master of business administration degree | Former |
Executive News
-
Report from Europe: U.S. Close vs. China Rebound
-
Alcoa Named Component of Dow Jones Sustainability Index for Eighth Consecutive Year
-
Alcoa says global aluminium demand to fall 5.5 pct -Bloomberg
-
Siemens To Settle Bribery Charges with Three Former Execs
-
Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
Bayer AG (BAY.F) May Be Ready for Deals After Lost Intervet Bid
-
Inventories May Temper Aluminum Rally
Industry Transcripts by Seeking Alpha
-
Deere & Company F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Nov 25, 2009about DE
-
Brown Shoe Co. Inc. Q3 2009 Earnings Call Transcript
on Nov 24, 2009about BWS
-
Daktronics Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 24, 2009about DAKT
-
Haynes International Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 24, 2009about HAYN
-
Valspar Corp. F4Q09 (Qtr End 30/10/09) Earnings Call Transcript
on Nov 23, 2009about VAL
